Gradientech in exclusive partnership with Hardy Diagnostics for the US and Canadian markets
The diagnostics company Gradientech today announces the exclusive partnership with Hardy Diagnostics for the commercialisation of its QuickMIC® system in the United States and Canada. QuickMIC is an ultra-rapid antibiotic susceptibility testing (AST) system designed to provide critical results for sepsis patients. Alongside this partnership, Hardy Diagnostics has decided to invest in Gradientech, becoming one of the company’s largest shareholders.
“With QuickMIC already being implemented in several European hospitals and the 510(k) study of QuickMIC recently started at clinical sites in the US, the important North American market is a key focus for us. We are therefore thrilled to announce our partnership with Hardy Diagnostics,” says Sara Thorslund, CEO of Gradientech.
Hardy Diagnostics, founded in 1980 by Jay Hardy, is a leading provider of microbiology products in North America. As the exclusive distributor of QuickMIC in the US and Canada, Hardy Diagnostics will leverage its extensive network and knowledge of the clinical microbiology landscape to bring this innovative AST testing system to healthcare providers across North America. “I believe few others can match Hardy Diagnostics' expertise in the US clinical microbiology market. Our two companies also share a common vision and place great value on our teams, ensuring a good partnership. We warmly welcome Hardy Diagnostics as both our exclusive distributor and a shareholder in Gradientech,” concludes Sara Thorslund.
“We found Gradientech to be an innovative company that has developed a revolutionary system for producing rapid antibiotic susceptibility testing for critically ill patients. We are both honoured and excited to become a part of this game changing technology,” says Jay Hardy, President of Hardy Diagnostics. “We are confident that the QuickMIC system will soon become the standard in the hospital laboratory and will be ultimately responsible for saving many lives. We look forward to our partnership with this dynamic company that shares our values.”
For further information, please contact:
Sara Thorslund, PhD, CEO
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se
Jay Hardy, CLS, SM (NRCM), President
Tel: +1 805 346 2766 Ext. 5674
hardyj@hardydiagnostics.com
About Hardy Diagnostics
Hardy Diagnostics is an FDA-licensed manufacturer of medical devices for microbiological testing with an ISO 13485 certified Quality Management System. Hardy Diagnostics manufactures 2,700 products, distributes more than 13,000 products, offers services to more than 10,000 laboratories, exports products to over 80 foreign distributors, and maintains a network of nine distribution centers throughout the United States. Hardy Diagnostics supports the microbiology needs of clinical, pharmaceutical, cosmetics and personal care, as well as the food and beverage industries. The company is 100% owned by the employees who work there. Serving laboratory scientists since 1980, Hardy Diagnostics' mission is to "produce and distribute the finest products for the detection of microorganisms and partner with its laboratory customers to diagnose and prevent disease." Hardy Diagnostics is headquartered in Santa Maria in California, US. Visit for more information.
About Gradientech
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden.
Visit www.gradientech.se for more information.
About QuickMIC®
The QuickMIC system's ultra-rapid and precise AST results enable sepsis patients to receive specific personalised guidance on the right antibiotic in record time. The modular design offers affordable scaling possibilities, making QuickMIC attractive to both small and large hospital laboratories. QuickMIC and its Gram-negative panel are CE marked and commercially available in Europe but not yet available for sale in the United States. Visit www.quickmic.se for more information.
Photo: Gradientech visiting Hardy Diagnostics at its headquarters in Santa Maria, California.
From the left: Andre Hsiung, Business Development and Jay Hardy, President of Hardy Diagnostics, Marc van Nuenen, VP Business Development US of Gradientech, and Christopher Catani, CEO of Hardy Diagnostics.
